Russell Hope

List of Publications by Year
in descending order

52 papers	3,697 citations	172457 29 h-index	189892 50 g-index
55 all docs	55 docs citations	55 times ranked	4666 citing authors

#	Article	IF	Citations
1	Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet, The, 2022, 399, 1303-1312.	13.7	889
2	Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infectious Diseases, The, 2022, 22, 35-42.	9.1	612
3	Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infectious Diseases, The, 2017, 17, 411-421.	9.1	269
4	Post-Harvest Fungal Ecology: Impact of Fungal Growth and Mycotoxin Accumulation in Stored Grain. European Journal of Plant Pathology, 2003, 109, 723-730.	1.7	227
5	Isolation of fluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum Â-lactamase from UK river water. Journal of Antimicrobial Chemotherapy, 2011, 66, 512-516.	3.0	88
6	Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. Journal of Antimicrobial Chemotherapy, 2008, 62, ii65-ii74.	3.0	86
7	Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007. Journal of Antimicrobial Chemotherapy, 2010, 65, 446-448.	3.0	86
8	Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?. Journal of Antimicrobial Chemotherapy, 2013, 68, 2667-2674.	3.0	83
9	Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. Journal of Antimicrobial Chemotherapy, 2006, 58, 320-326.	3.0	78
10	Cephalosporin resistance mechanisms in Escherichia coli isolated from raw chicken imported into the UK. Journal of Antimicrobial Chemotherapy, 2010, 65, 2534-2537.	3.0	78
11	Variation in the genetic environments of blaCTX-M-15 in Escherichia coli from the faeces of travellers returning to the United Kingdom. Journal of Antimicrobial Chemotherapy, 2011, 66, 1005-1012.	3.0	76
12	Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. Journal of Antimicrobial Chemotherapy, 2006, 57, 1012-1014.	3.0	67
13	Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. Journal of Antimicrobial Chemotherapy, 2008, 62, ii41-ii54.	3.0	62
14	Characterization of Â-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). Journal of Antimicrobial Chemotherapy, 2012, 67, 1354-1358.	3.0	55
15	Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum Â-lactamases in nursing homes in Belfast, UK. Journal of Antimicrobial Chemotherapy, 2011, 66, 297-303.	3.0	54
16	Environmental Factors and Interactions with Mycobiota of Grain and Grapes: Effects on Growth, Deoxynivalenol and Ochratoxin Production by Fusarium culmorum and Aspergillus carbonarius. Toxins, 2010, 2, 353-366.	3.4	51
17	Comparative virulence of urinary and bloodstream isolates of extra-intestinal pathogenicEscherichia coliin aGalleria mellonellamodel. Virulence, 2015, 6, 145-151.	4.4	50
18	The health and cost burden of antibiotic resistant and susceptible Escherichia coli bacteraemia in the English hospital setting: A national retrospective cohort study. PLoS ONE, 2019, 14, e0221944.	2.5	50

#	Article	IF	Citations
19	Real-time PCR for detection of the O25b-ST131 clone of Escherichia coli and its CTX-M-15-like extended-spectrum Î²-lactamases. International Journal of Antimicrobial Agents, 2010, 36, 355-358.	2.5	49
20	Is Pantonâ€“Valentine leucocidin associated with the pathogenesis of Staphylococcus aureus bacteraemia in the UK?. Journal of Antimicrobial Chemotherapy, 2007, 60, 402-405.	3.0	48
21	Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes. Journal of Antimicrobial Chemotherapy, 2013, 68, 153-158.	3.0	48
22	Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. Journal of Antimicrobial Chemotherapy, 2008, 62, ii55-ii63.	3.0	42
23	Healthcare-associated COVID-19 in England: A national data linkage study. Journal of Infection, 2021, 83, 565-572.	3.3	42
24	Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes. Journal of Antimicrobial Chemotherapy, 2008, 62, ii15-ii28.	3.0	41
25	Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06. Journal of Antimicrobial Chemotherapy, 2008, 62, ii75-ii85.	3.0	41
26	Emergent and evolving antimicrobial resistance cassettes in community-associated fusidic acid and meticillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents, 2015, 45, 477-484.	2.5	39
27	Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom. Emerging Infectious Diseases, 2018, 24, .	4.3	37
28	Activity of BAL30072 alone or combined with Â-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. Journal of Antimicrobial Chemotherapy, 2013, 68, 1601-1608.	3.0	34
29	National surveillance of bacterial and fungal coinfection and secondary infection in COVID-19 patients in England: lessons from the first wave. Clinical Microbiology and Infection, 2021, 27, 1658-1665.	6.0	31
30	Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. Journal of Antimicrobial Chemotherapy, 2008, 62, ii87-ii95.	3.0	28
31	Effect of antibiotic stewardship interventions in primary care on antimicrobial resistance of Escherichia coli bacteraemia in England (2013â€“18): a quasi-experimental, ecological, data linkage study. Lancet Infectious Diseases, The, 2021, 21, 1689-1700.	9.1	28
32	Improving feedback of surveillance data on antimicrobial consumption, resistance and stewardship in England: putting the data at your Fingertips. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw536.	3.0	26
33	Exploring the relationship between primary care antibiotic prescribing for urinary tract infections, Escherichia coli bacteraemia incidence and antimicrobial resistance: an ecological study. International Journal of Antimicrobial Agents, 2018, 52, 790-798.	2.5	26
34	ISEcp1-mediated transposition of linked blaCTX-M-3 and blaTEM-1b from the IncI1 plasmid pEK204 found in clinical isolates of Escherichia coli from Belfast, UK. Journal of Antimicrobial Chemotherapy, 2011, 66, 2263-2265.	3.0	22
35	The contribution of hospital-acquired infections to the COVID-19 epidemic in England in the first half of 2020. BMC Infectious Diseases, 2022, 22, .	2.9	22
36	Activity of faropenem against cephalosporin-resistant Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2007, 59, 1025-1030.	3.0	18

#	Article	IF	Citations
37	Rising rates of hospital-onset Klebsiella spp. and Pseudomonas aeruginosa bacteraemia in NHS acute trusts in England: a review of national surveillance data, August 2020â€“February 2021. Journal of Hospital Infection, 2022, 119, 175-181.	2.9	16
38	Quantifying the contribution of pathways of nosocomial acquisition of COVID-19 in English hospitals. International Journal of Epidemiology, 2022, 51, 393-403.	1.9	14
39	Assessment of Mortality and Hospital Admissions Associated with Confirmed Infection with SARS-CoV-2 Variant of Concern VOC-202012/01 (B.1.1.7) a Matched Cohort and Time-to-Event Analysis. SSRN Electronic Journal, 0, , .	0.4	13
40	In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci. International Journal of Antimicrobial Agents, 2013, 41, 213-217.	2.5	11
41	Impact of introducing procalcitonin testing on antibiotic usage in acute NHS hospitals during the first wave of COVID-19 in the UK: a controlled interrupted time series analysis of organization-level data. Journal of Antimicrobial Chemotherapy, 2022, 77, 1189-1196.	3.0	9
42	Replacement of Enterococcus faecalis by Enterococcus faecium as the predominant enterococcus in UK bacteraemias. JAC-Antimicrobial Resistance, 2021, 3, dlab185.	2.1	7
43	Trends in rates of incidence, fatality and antimicrobial resistance among isolates of Pseudomonas spp. causing bloodstream infections in England between 2009 and 2018. Results from a national voluntary surveillance scheme. Journal of Hospital Infection, 2021, , .	2.9	5
44	Ecophysiology of Fusarium culmorum and mycotoxin production. Advances in Experimental Medicine and Biology, 2006, 571, 123-136.	1.6	4
45	Zone breakpoints, by the CLSI disc method, for 15 Âg tigecycline discs corresponding to EUCAST MIC breakpoints. Journal of Antimicrobial Chemotherapy, 2010, 65, 2262-2264.	3.0	4
46	Nosocomial Transmission of C. difficile in English Hospitals from Patients with Symptomatic Infection. PLoS ONE, 2014, 9, e99860.	2.5	4
47	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	4
48	Using linked electronic health records to report healthcare-associated infections. PLoS ONE, 2018, 13, e0206860.	2.5	3
49	Using hospital network-based surveillance for antimicrobial resistance as a more robust alternative to self-reporting. PLoS ONE, 2019, 14, e0219994.	2.5	3
50	How do the epidemiology of paediatric methicillin-resistant Staphylococcus aureus and methicillin-susceptible Staphylococcus aureus bacteraemia differ?. Journal of Medical Microbiology, 2017, 66, 737-743.	1.8	3
51	Proposed disc zone breakpoints for doripenem for use with the BSAC disc susceptibility testing method. Journal of Antimicrobial Chemotherapy, 2010, 65, 1547-1548.	3.0	1
52	Preface. Journal of Antimicrobial Chemotherapy, 2011, 66, iv1-iv1.	3.0	0